Renin-angiotensin system inhibitor is associated with the reduced risk of all-cause mortality in COVID-19 among patients with/without hypertension.
10.1007/s11684-021-0850-9
- Author:
Huai-Yu WANG
1
;
Suyuan PENG
1
;
Zhanghui YE
2
;
Pengfei LI
2
;
Qing LI
2
;
Xuanyu SHI
1
;
Rui ZENG
3
;
Ying YAO
4
;
Fan HE
3
;
Junhua LI
3
;
Liu LIU
3
;
Shuwang GE
3
;
Xianjun KE
5
;
Zhibin ZHOU
5
;
Gang XU
3
;
Ming-Hui ZHAO
6
;
Haibo WANG
7
;
Luxia ZHANG
8
;
Erdan DONG
9
,
10
,
11
Author Information
1. National Institute of Health Data Science at Peking University, Beijing, 100191, China.
2. Peking University Advanced Institute of Information Technology, Hangzhou, 311215, China.
3. Department of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
4. Department of Clinical Nutrition, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
5. Taikang Tongji (Wuhan) Hospital, Wuhan, 430050, China.
6. Renal Division, Department of Medicine, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, 100034, China.
7. First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China.
8. National Institute of Health Data Science at Peking University, Beijing, 100191, China. zhanglx@bjmu.edu.cn.
9. Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital
10. Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Ministry of Health
11. Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Beijing Key Laboratory of Cardiovascular Receptors Research, Beijing, 100191, China.
- Publication Type:Journal Article
- Keywords:
COVID-19;
RAS inhibitor;
all-cause mortality;
hypertension
- MeSH:
Angiotensin Receptor Antagonists/therapeutic use*;
Angiotensin-Converting Enzyme Inhibitors/therapeutic use*;
COVID-19;
Humans;
Hypertension/drug therapy*;
Renin-Angiotensin System;
Retrospective Studies
- From:
Frontiers of Medicine
2022;16(1):102-110
- CountryChina
- Language:English
-
Abstract:
Consecutively hospitalized patients with confirmed coronavirus disease 2019 (COVID-19) in Wuhan, China were retrospectively enrolled from January 2020 to March 2020 to investigate the association between the use of renin-angiotensin system inhibitor (RAS-I) and the outcome of this disease. Associations between the use of RAS-I (angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)), ACEI, and ARB and in-hospital mortality were analyzed using multivariate Cox proportional hazards regression models in overall and subgroup of hypertension status. A total of 2771 patients with COVID-19 were included, with moderate and severe cases accounting for 45.0% and 36.5%, respectively. A total of 195 (7.0%) patients died. RAS-I (hazard ratio (HR)= 0.499, 95% confidence interval (CI) 0.325-0.767) and ARB (HR = 0.410, 95% CI 0.240-0.700) use was associated with a reduced risk of all-cause mortality among patients with COVID-19. For patients with hypertension, RAS-I and ARB applications were also associated with a reduced risk of mortality with HR of 0.352 (95% CI 0.162-0.764) and 0.279 (95% CI 0.115-0.677), respectively. RAS-I exhibited protective effects on the survival outcome of COVID-19. ARB use was associated with a reduced risk of all-cause mortality among patients with COVID-19.
